



VALO
THERAPEUTICS

Therapeutic Vaccination Against Cancer - PeptiCRAd™

International Cancer Cluster, June 3rd, 2019


Valo Therapeutics



- Spin-out from University of Helsinki in late 2016
- Reinventing cancer Immuno-therapeutics: using Oncolytic viruses as powerful peptide vaccine delivery system/adjuvants to treat solid tumours
 - PeptiCRAd - Oncolytic Adenoviruses
 - PeptiENV - Oncolytic enveloped viruses including HSV, Vaccinia, VSV
- 1st PeptiCRAd product expected to be in the clinic Q4 2019/Q1 2020

What is PeptiCRAd?


Peptide vaccine



PROS: Tumor-specific immune responses

CONS: Low immunogenicity → mainly humoral immune response, clinical benefit rarely seen in cancer patients

Oncolytic virus




PROS: Highly immunogenic → robust activation of the immune system, primarily CD8+ T cell response

CONS: Primarily triggers anti-virus immunity, tumor-targeted responses are rarely seen in cancer patients

Tumor specific

Highly immunogenic

PeptiCRAd




PeptiCRAd innovatively and synergistically combines the best features of these two technologies → a robust immune response against multiple tumor-specific targets simultaneously

CPIs provide durable responses in tumours with pre-existing anti-tumour immune responses. PeptiCRAd designed to redirect immune responses from virus towards tumours synergistically with CPIs.


What is PeptiCRAd?

Oncolytic Adenovirus
(negative charge)




- Tumor-specific replication
- Immune-boosting modifications
- Tumor-targeting Modifications

Tumor-specific peptides
(+ positive charge)



- Clinically proven vaccine peptides
 - Novel tumor peptides
- Unique patient-specific neoantigens

Patient-specific treatment
(electrostatic complex)




- Multiple different tumor-specific peptides can be adsorbed onto one PeptiCRAd
- Multiple tumor-specific antigens can be targeted simultaneously

PeptiCRAd is an oncolytic adenovirus vaccine platform, where immunogenic tumor peptides are adsorbed onto the negatively charged viral capsid

PeptiCRAd-1 is superior to standard peptide vaccine in priming tumor-specific CD8+ T-cells in clinically relevant humanized mouse melanoma model




- Priming treatment on days 1,2,3 → Assessment of tumor-specific CD8+ T-cells on day 10
- RESULT: 60% (9/15) of PeptiCRAd-treated animals showed an induction of tumor-specific CD8+ T-cells post-priming




Collaboration with DNATrix



Clinically Effective Viruses




Tumor-specific peptides



+

=

Armed Oncolytic Vaccine



Provides oncolysis, gene expression and anti-tumor T-cell response



- Synergistic technologies and expertise
- Advancement of PeptiCRAd platform to the clinic with already clinically validated oncolytic adenovirus in up to 4 solid tumour indications
- Sharing of development costs
- Valo retains rights to development of its own PeptiCRAds in all other indications
- Presence in US and EU
- Seeking further partnerships to develop PeptiCRAd and PeptiENV platforms in new indications

PeptiCRAd-1 is superior to standard peptide vaccine in priming tumor-specific CD8+ T-cells in clinically relevant humanized mouse melanoma model



- Priming treatment on days 1,2,3 → Assessment of tumor-specific CD8+ T-cells on day 10
- RESULT: 60% (9/15) of PeptiCRAd-treated animals showed an induction of tumor-specific CD8+ T-cells post-priming

